• Skip to primary navigation
  • Skip to main content
  • Skip to footer
PanTher Therapeutics

PanTher Therapeutics

  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact
homepanthertx

panthertx

World’s Largest Medtech Accelerator Announces 61 Startups for its 2023 Cohort

June 6, 2023 News

PanTher Therapeutics has been selected for the prestigious MedTech Innovator 2023 Program in the mid-stage company cohort. Among a competitive pool of ~1,150 company applicants, nearly 200 advanced to the in-person pitch and partnering events on the MedTech Innovator Road Tour. Over 400 industry experts completed four months of diligence, selecting PanTher to be among the 61 startups selected for this cohort.

Women Who Lead in Life Sciences Series features Laura Indolfi

May 12, 2023 News

Laura Indolfi, CEO and Co-Founder of PanTher Therapeutics is featured in the Massachusetts Life Sciences Center’s Series “Women Who Lead in Life Sciences” published in the print edition of the Boston Business Journal. PanTher Therapeutics is developing the next cancer treatment by targeting the disease at its source.

Laura Indolfi Featured as a Guest on MedTech Money Podcast Episode 119

April 28, 2023 News

PanTher’s CEO and Founder, Laura Indolfi, joins MedTech Monday podcast host Giovanni Lauricella to discuss angels vs. institutional money, Silicon Valley Bank, pitching to the wrong people, psychology that you must have while raising money, her Ted Talk, and so much more.

PanTher Presents Phase 1 Trial-In-Progress Poster for Pancreatic Cancer Study at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

January 20, 2023 News

PanTher Therapeutics presents “Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma – A Trial in Progress” poster at the American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., The poster highlights the trial-in-progress for the treatment of borderline resectable or locally advanced pancreatic ductal adenocarcinoma ongoing in Australia. PanTher Therapeutics’ CEO Laura Indolfi and study Principal Investigator John Zalcberg are present to answer any questions.  

PanTher Therapeutics Billboard is Live in Times Square, New York, NY

November 7, 2022 News

PanTher Therapeutics’ mission of Attacking Cancer at the Source™ is shared from the famous Times Square billboards in New York City November 7-13, 2022.  As part of a sponsored campaign with Brex, PanTher displays their mission to the mass of people visiting the major commercial intersection, tourist destination, and entertainment hub that is Times Square.

PanTher’s approach of “Attacking Cancer the Source” featured in the Nature Biopharma Dealmakers publication focused on the oncology landscape

March 1, 2022 News

PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform. Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. In a highly competitive innovative drug discovery market, PanTher’s technology focuses on optimizing the route of administration to unlock a drug’s full potential.

Footer

Twitter LinkedIn

PanTher Therapeutics, Inc

Austin, TX
Watertown, MA

PanTher Therapeutics © 2022 All Rights Reserved

Terms of Use Privacy Policy Cookie Policy Accessibility Statement

logo
  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact